Wire · opportunities
AI tool designed to predict breast cancer recurrence cleared by FDA
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 October 2026 · Fusion42 review
The FDA has cleared TumorSight Risk, the first AI-powered MRI-based tool to predict breast cancer recurrence risk for early-stage hormone receptor-positive, HER2-negative patients. This tool accelerates risk assessment by delivering results in under two hours without requiring additional tissue samples.
This Wire brief sits within Fusion42's coverage of Digital Health, and 6 sources have reported it between 15 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
You can now build diagnostic tools that bypass long waits for test results using AI-powered imaging analysis cleared by the FDA. This opens faster patient risk profiling as a competitive entry point in cancer care technology.
◆ Coverage
6 sources · first reported 15 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics